Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 91.

https://doi.org/10.1182/blood-2025-91

Published: 2025

Journal Articles

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Blood (2025) 146 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2025-1413

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Lu Zhang, Rui Chen, Yujun Dong, Qin Wang, Liangming Ma, Jun Zhang, Zi-qiang Li, Jian Li

Blood (2025) 146 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2025-4787

Published: 2025

Journal Articles

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Blood (2025) 146 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2025-5584

Published: 2025

Journal Articles

The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.

Tao Wang, Jia Wei, Liangming Ma

Blood (2025) 146 (Supplement 1): 5986.

https://doi.org/10.1182/blood-2025-5986

Published: 2025

Journal Articles

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

Hu Qian, Xinwei Wang, Liping Yang, Juan Peng, Jie Zhao, Shaolong He, Jin Zhao, Jiaqi Guo, Yuekun Fang, Fankai Meng, Yang Cao, Lifang Huang, Junni Wei, Liangming Ma, Li-Ping Su, Weiwei Tian, Yicheng Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 7834.

https://doi.org/10.1182/blood-2024-205222

Published: 2024

Journal Articles

SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Blood (2024) 144 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2024-199381

Published: 2024

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Journal Articles

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

Xiaolu Zhu, Hui Liu, Zhao Wang, Zhongxing Jiang, Liangming Ma, Min Wang, Jiamin Zhang, Zhuoyu An, Yejun Wu, Yun He, Haixia Fu, Yingjun Chang, Lanping Xu, Kaiyan Liu, Xiao Jun Huang, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2023-184342

Published: 2023

Journal Articles

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Xinyi Lu, Xinyue Chen, Liping Yang, Qiong Yao, Jie Zhao, Shaolong He, Liangming Ma, Chunrui Li, JIA Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 12545–12546.

https://doi.org/10.1182/blood-2022-166285

Published: 2022

Journal Articles

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

Xinyue Chen, Xinyi Lu, Xinwei Wang, Liangming Ma, JIA Wei, Chunrui Li, Junni Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 11203–11204.

https://doi.org/10.1182/blood-2022-168896

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2022) 140 (Supplement 1): 12637–12639.

https://doi.org/10.1182/blood-2022-169057

Published: 2022

Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang

Blood (2021) 138 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2021-149502

Published: 2021

Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Blood (2021) 138 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2021-152542

Published: 2021

Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Blood (2019) 134 (Supplement_1): 5493.

https://doi.org/10.1182/blood-2019-125447

Published: 2019

Journal Articles

Adoptive Immunotherapy with Donor Lymphocyte Infusion after Allogeneic Nonmyeloablative Stem Cell Transplantation.

Zhenhua Qiao, Zhuanzhen Zheng, Fang Ye, Liangming Ma, Rong Gong

Blood (2005) 106 (11): 5196.

https://doi.org/10.1182/blood.V106.11.5196.5196

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

The Combination of Iguratimod and Danazol Versus Danazol As a Treatment of Corticosteroid-Resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-Label Trial

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Adoptive Immunotherapy with Donor Lymphocyte Infusion after Allogeneic Nonmyeloablative Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only